SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

Tilray is trending amid reports that the US president is considering reclassifying marijuana, which has sparked significant community discussion around potential benefits like tax relief and increased investment.  Traders are actively debating the likelihood and impact of the potential policy change, with some anticipating a major short squeeze while others express skepticism. Overall, the news has injected volatility and renewed interest in cannabis stocks.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and the FC SAN business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom ($AVGO) is trending after earnings, with a mixed community sentiment as the stock experiences a sharp sell-off despite strong results and raised guidance, leading to speculation of manipulation and an AI bubble. Discussions revolve around the potential reasons for the decline, including profit-taking, margin concerns, and the overall market rotation out of tech. Despite the negative price action, many analysts have raised their price targets, fueling debate on whether this is a buying opportunity or a sign of further downside.

The GEO Group, Inc. engages in the design, financing, development, and support services for secure facilities, processing centers, and community re-entry facilities. It operates through the following segments: U.S. Secure, Electronic Monitoring and Supervision, Reentry, and International Services. The U.S. Secure Services segment encompasses the United States-based public-private partnership corrections and detention business. The Electronic Monitoring and Supervision Services segment conducts its services in the U.S. The Reentry Services Segment consists of various community-based and reentry services. The International Services segment consists of public-private partnership secure services operations in Australia and South Africa. The company was founded by George C. Zoley in 1984 and is headquartered in Boca Raton, FL.

Geo Group, Inc.

Geo Group is trending as analysts updated their target price forecasts, sparking renewed community discussion. Community members are also discussing the company's potential to benefit from shifts in immigration policy and contract wins, while others debate the ethical implications of investing in private prisons. The stock's movement appears tied to broader political and policy cycles related to immigration and detention.

Advisorshares Trust - AdvisorShares Pure US Cannabis ETF

AdvisorShares Pure US Cannabis ETF

MSOS is trending amid speculation around potential cannabis rescheduling and executive action, driving optimism in the sector. The community is focused on potential catalysts like Trump's actions and Supreme Court decisions that could lead to significant re-rating and M&A activity. Discussions also center on identifying undervalued plays within the cannabis space, particularly those poised for substantial growth if regulatory changes materialize.

SU Group Holdings Ltd. engages in the provision of security-related engineering services, and security guarding and screening services. It operates through the Security-Related Engineering Services and Security Guarding and Screening Services segments. The company was founded by Ming Chan in 1998 and is headquartered in Hong Kong.

SU Group Holdings Ltd. - Ordinary Shares - Class A

SU Group Holdings Ltd

SUGP is trending as traders discuss its low float, potential short squeeze, and possible breakout, drawing comparisons to other HK stocks like $SMX and $OCG. Community members are closely watching for a golden cross setup and anticipate upward momentum if the stock moves above the $6 and $8 levels. The stock is known for crazy moves and potential for an after-hours run.

Snap, Inc. operates as a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snap is trending as investors debate its future, with some citing improving free cash flow and AI potential as reasons to buy, while others express concerns about leadership and profitability. Discussions also center around a potential buyout and the upcoming specs release. Sentiment appears mixed as the stock experiences volatility amid broader market fluctuations.

RYTHM, Inc. engages in the development of hardware and software solutions for indoor agriculture. The company was founded on June 6, 2016 and is headquartered in Rolling Meadows, IL.

RYTHM Inc.

RYTHM Inc. is trending amid community discussions about potential catalysts from its pipeline and high trading volume. Some traders are debating the offering's risk and watching for short covering, while others are focused on technical analysis and potential for a significant price move. Active discussions and user disputes are contributing to the stock's visibility.

Argo Blockchain Plc operates as a blockchain technology company focused on large-scale mining of Bitcoin and other cryptocurrencies. It mines using purpose-built computers to solve cryptographic algorithms in the blockchain in exchange for rewards and fees denominated in the native token of that blockchain network. The company was founded in 2017 and is headquartered in London, the United Kingdom.

Argo Blockchain Plc - ADR

Argo Blockchain Plc

Argo Blockchain is trending due to discussions around its reverse stock split and London Stock Exchange delisting, with the community debating potential impacts. Some traders anticipate a rebound and short squeeze given the low float post-split, while others express skepticism about the company's financial health and potential for further dilution. Overall, the conversation reflects a mix of speculative hope and concern amidst restructuring efforts.

lululemon athletica, Inc. engages in the business of designing, distributing, and retailing technical athletic apparel, footwear, and accessories. It operates through the following segments: Company-Operated Stores, Direct to Consumer, and Other. The company was founded by Dennis James Wilson in 1998 and is headquartered in Vancouver, Canada.

Lululemon Athletica inc.

Lululemon Athletica Inc

Lululemon is trending due to a surprise CEO exit and a Q3 earnings beat, sparking discussions about the company's future leadership and strategic direction. The approval of a $1B buyback is fueling bullish sentiment, though some express concerns over margin pressure and softness in the Americas. Community members are actively debating whether this marks the start of a sustained turnaround or a temporary reprieve.

Aurora Cannabis, Inc. engages in the production, distribution, and sale of cannabis and cannabis-derivative products. It operates through the Cannabis and Plant Propagation segments. The company was founded by Terry Booth and Steve Dobler on December 21, 2006 and is headquartered in Edmonton, Canada.

Aurora Cannabis Inc

Aurora Cannabis is trending alongside other cannabis stocks amid speculation that the U.S. federal government might ease marijuana restrictions, with community members actively discussing the potential impacts of policy changes. Chatter revolves around an executive order from President Trump to reclassify cannabis, although some traders are wary of potential 'pump and dump' scenarios. Investors are weighing the implications for legacy cannabis companies like ACB given the broader sector's volatile history.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>AXIL’s hearing products will hit over 3,700 Walmart stores, marking its largest single retail placement ever.&nbsp;</li><li>AXIL already has partnerships with Costco’s 300-plus retail and online stores.&nbsp;</li><li>Shares of AXIL are up over 30% in the last year.&nbsp;</li></ul>AXIL Brands, Inc. (AXIL) shares soared in Thursday’s premarket trade after the company announced a national retail distribution agreement with Walmart, which will bring its hearing protection and enhancement products to a massive new audience.The company said that under the agreement, AXIL's products, including its new AXIL® X30 LT earplugs, would be available in over 3,700 Walmart stores.&nbsp;According to the statement, the Walmart rollout represents the firm’s largest single retail placement to date.Shares of AXIL soared over 150% on the announcement.&nbsp;<h2 class="st-heading-2">New Horizons</h2>AXIL’s debut at Walmart is slated for February 2026, with the launch of a new product, the AXIL® X30 LT in-ear hearing protection plugs, available in retail outlets.In September this year, AXIL&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://goaxil.com/blogs/press-releases/axil-brands-launches-nationwide-at-costco-with-axil-xcor-se-advanced-hearing-protection-and-enhancement-earbuds">partnered with Costco</a> to take its earbuds to over 300 stores in the U.S. and eventually expanded to offer them on Costco’s online platform as well.&nbsp;Between Walmart and Costco placements, Axil’s expansion gives it access to millions of American consumers. In the latest statement, the company said that these partnerships position it for faster growth and greater brand visibility starting in 2026.“This partnership is a testament to the performance, value, and consumer demand for our products and will make our best-in-class hearing protection and enhancement technology available to millions of consumers who shop at Walmart every day,” Jeff Toghraie, Chairman and CEO at AXIL Brands, said.&nbsp;In October, <a href="https://stocktwits.com/symbol/AXIL">AXIL</a> announced its first-quarter (Q1) 2026 results, reporting a 17.2% increase in quarterly sales and an improvement in operating income of $0.4 million, compared to an operating loss in the same period last year.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around AXIL jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume jumped to ‘extremely high’ levels at the time of writing.<img src="https://news.stocktwits-cdn.com/Screenshot_2025_12_11_at_5_03_15_PM_png_87987f7875.webp" alt="Screenshot 2025-12-11 at 5.03.15 PM.png">One user stressed their bullish outlook on the stock.&nbsp;<stembedurl>https://stocktwits.com/nader_1/message/638834530</stembedurl>Shares of AXIL are up over 30% in the last year.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

The exterior of a Walmart store in Hollywood, Florida. (Photo by Joe Raedle/Getty Images)

 AXIL Stock Just Rocketed Over 150% Today — What’s The Walmart Angle? 

AXIL Brands announced a partnership with Walmart that would bring its products to the stores of America’s largest retailer.

Equity

<ul class="summary-bullets"><li>SENTI-202, the immune cell therapy cancer treatment, received a Regenerative Medicine Advanced Therapy (RMAT) designation that would make it eligible for quicker reviews.</li><li>This is the second FDA designation for the treatment this year.&nbsp;</li><li>On Stocktwits, retail sentiment for the stock rose to ‘extremely bullish’ territory while message volume jumped to ‘extremely high’ levels at the time of writing. &nbsp;</li></ul>Shares of Senti Biosciences, Inc. (SNTI) surged over 20% on Tuesday’s premarket trading after the company announced positive news around its cancer treatment.&nbsp;The clinical-stage biotech company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.sentibio.com/news-releases/news-release-details/senti-bio-announces-updated-senti-202-clinical-data-ongoing">announced</a> in a press release that the U.S. Food and Drug Administration (FDA) gave SENTI-202, an immune cell therapy cancer treatment, a Regenerative Medicine Advanced Therapy (RMAT) designation.&nbsp;<h2 class="st-heading-2">What Does This Mean?</h2>The RMAT designation from the FDA for the company’s cancer treatment indicates an expedited development and review, providing benefits similar to the FDA’s Breakthrough Therapy and the Fast Track programs such as higher interactions with the Agency through the development process as well as eligibility for quicker and even priority reviews.“This significant FDA designation validates both the tremendous need for better treatments for R/R AML and the promise of SENTI-202 to transform the therapeutic landscape for this notoriously aggressive cancer,” said Timothy Lu, Co-Founder and CEO of Senti Biosciences, in the press release. “We are incredibly pleased with the exciting clinical progress we recently shared at the ASH conference on SENTI-202.”Data from its ongoing trial showed a 50% overall response rate and 42% complete remission at the recommended Phase 2 dose, the company revealed. Earlier this year, the U.S. FDA granted the treatment Orphan Drug Designation.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around&nbsp;<a href="https://stocktwits.com/symbol/SNTI">SNTI</a> jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:1284/149;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_09_at_7_13_22_PM_png_c037e194c0.webp" alt="On Stocktwits, retail sentiment around&nbsp;SNTI jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘extremely high’ levels." width="1284" height="149"></figure>One user on the platform predicted that STNI’s share price could go up to $5. The stock was trading around $2.85 at the time of writing.&nbsp;<stembedurl>https://stocktwits.com/Stratsys/message/638587949</stembedurl>Shares of SNTI have fallen over 37% year to date.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, a medicine pill is seen in a hand dressed in a medical glove with the U.S. FDA logo in the background. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images) 

SNTI Shares Surge Over 20% In Pre-Market Trade After FDA RMAT Designation For Cancer Treatment

Senti Biopharma shares rallied in premarket trading on Tuesday after its cancer treatment received a positive designation from the U.S. FDA.

SNTI Shares Surge Over 20% In Pre-Market Trade After FDA RMAT Designation For Cancer Treatment 

<ul class="summary-bullets"><li>Roth Capital sees potential FDA clearance for the software.</li><li>The FDA may want the company to use a different predicate device, pursue a different regulatory pathway, or provide additional data, the analyst said.&nbsp;</li><li>HeartBeam is now evaluating launching its 3D ECG system, which received FDA clearance in December 2024.</li></ul>Shares of HeartBeam, Inc. (BEAT) slumped 58% on Friday afternoon after the company said that the U.S. Food and Drug Administration refused clearance for its 12-Lead Electrocardiogram (ECG) Synthesis Software for arrhythmia assessment.The medical technology company said that it received a ‘not substantially equivalent’ letter from the FDA. A "Not Substantially Equivalent" (NSE) letter is an official notification from the FDA stating that a new medical device is not considered substantially equivalent to a legally marketed predicate device.The company said that it will be working with the agency to get to a resolution and expressed confidence in its clinical data. Earlier this month, HeartBeam had touted FDA clearance for the software as a major inflection point for the company.The company is now evaluating launching its 3D ECG system which received FDA clearance in December 2024.<h2 class="st-heading-2">Analyst Takeaway</h2>Roth Capital, however, sees potential FDA clearance for the software. The FDA may want the company to use a different predicate device, pursue a different regulatory pathway, or provide additional data, it said.While resolving the pathway for the 12-lead ECG synthesis software, management may decide to roll out the foundational 3D ECG system to concierge medical practices, preventive cardiology clinics, and hospital-at-home programs, the analyst said, as per The Fly.The analyst kept a ‘Buy’ rating on HeartBeam with a $4 price target. The price target represents a potential upside of over 138% from the stock’s closing price on Thursday.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/BEAT">BEAT stock</a> rose from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.A Stocktwits user echoed Roth Capital’s opinion and said that the stock would beat $5 on FDA approval.<stembedurl>https://stocktwits.com/jamestocklover/message/637108009</stembedurl>Another noted that an NSE letter is not the end.<stembedurl>https://stocktwits.com/Rolltide2020/message/637103348</stembedurl>BEAT stock is down by 70% this year and by about 75% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/will-scot-stock-surges-after-baird-upgrade-analyst-calls-q3-a-watershed-quarter/cLPMv4RREfb">WillScot Stock Surges After Baird Upgrade – Analyst Calls Q3 A ‘Watershed Quarter’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

HeartBeam Stock Slumps After FDA Refuses Clearance For ECG Software

The company said it will work with the agency to reach a resolution and expressed confidence in its clinical data.

<ul><li>According to Telomir, more than 60,000 new cases of Leukemia are diagnosed each year in the U.S.</li><li>Leukemia cells rely heavily on iron as a fuel source, and Telomir-1 in previous research demonstrated the ability to reduce intracellular iron levels.&nbsp;</li><li>The new findings expand on the experimental drug’s previously reported activity in triple-negative breast, pancreatic, and aggressive prostate cancer models.</li></ul>Telomir Pharmaceuticals, Inc. (TELO) said on Friday that its investigational compound Telomir-1 killed aggressive human leukemia (HL60) cells in an in-vitro study.HL60 leukemia cells were treated with Telomir-1, which produced a clear, dose-dependent reduction in viable leukemia cells, indicating strong activity, the company said.Leukemia is a cancer of the blood and bone marrow defined by the uncontrolled growth of abnormal white blood cells.<a href="https://stocktwits.com/symbol/TELO">TELO shares</a> rose 8% at the time of writing.<h2 class="st-heading-2">New Findings</h2>According to Telomir, more than 60,000 new cases of Leukemia are diagnosed each year in the U.S. Leukemia cells rely heavily on iron as a fuel source, and Telomir-1 in previous research demonstrated the ability to reduce intracellular iron levels."The potency observed in HL60 leukemia cells is consistent with the broader biological patterns we have seen throughout Telomir's research…These findings support our scientific framework for evaluating Telomir-1 and inform the ongoing advancement of our overall oncology research program," the company’s chief scientific advisor, Itzchak Angel,<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://telomirpharma.com/#"> said</a>.The new findings expand on the experimental drug’s previously reported activity in triple-negative breast, pancreatic, and aggressive prostate cancer models. The compound is the company’s lead candidate.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around TELO jumped from ‘bearish’ to ‘bullish’ territory over the past 24 hours, while message volume levels rose from ‘extremely low’ to ‘high’ levels.TELO stock is down 66% this year and by 69% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/google-ai-infra-chief-must-double-ai-compute-twice-a-year/cLPMFWiREOK">Google AI Infra Chief Says It Must Double AI Compute Twice A Year To Meet Demand: Report</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, the Telomir Pharmaceuticals logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

TELO Stock Jumps Pre-market After Early Study Results Show Leukemia Cell Death 

HL60 leukemia cells were treated with Telomir-1, which produced a clear, dose-dependent reduction in viable leukemia cells, indicating strong activity, the company said.

<ul class="summary-bullets"><li>Matt Kinsella said that computing is not the only product coming from quantum technologies.</li><li>There's a&nbsp;wide range of other products, including quantum sensors, quantum clocks, RF antennas, gravimeters, and&nbsp;different types of inertial sensing equipment.</li><li>Citing McKinsey’s research, the executive said Infleqtion’s total addressable market (TAM) is about $160 billion.</li></ul>Quantum computing company Infleqtion is set to go public via a Special Purpose Acquisition Company (SPAC) deal with Churchill Capital Corp. (CCCX), a blank-check company founded by ex-Citi executive Michael Klein. The ongoing government shutdown may have pushed back the going-public timeline slightly.&nbsp;Still, it hasn’t dampened Infleqtion CEO Matt Kinsella's optimism&nbsp;about&nbsp;what the future holds out for the company.Since the SPAC deal was announced, <a href="https://stocktwits.com/symbol/CCCX">Churchill Capital stock</a> has gained about 60%.Stockwits sat down with Kinsella, a former venture capitalist and a breakthrough technology evangelist, for a freewheeling chat about Inflqeqtion and its way forward:Here are excerpts from the interview:<h2 class="st-heading-2">Quantum Tech Is Much More Than Computing</h2>Kinsella attributed the skepticism toward the quantum computing industry to&nbsp;the pushed-out timelines. “For the last 20 years, it's always kind of been, oh, in five years we'll have quantum computing. It's always been this kind of rolling five years, and when you get there, it's five years from now we'll have it, and then five years from now you'll have it,” he said.The skepticism, according to the executive, stems from a bucket of misconceptions — that computing is the only product&nbsp;emerging from&nbsp;quantum technologies. “There's a whole umbrella of other types of products, such as quantum sensors, where quantum is already developing products that are truly orders of magnitude better than classical standards.” He also mentioned products such as quantum clocks, RF antennas, gravimeters, and other types of inertial sensing equipment.<h2 class="st-heading-2">Quantum Space In An Excited State</h2>Quantum computing stocks began the year on a slow note as they digested the torrid gains made in 2024, most of which occurred late in the year. These stocks also moved in tandem with the broader market when it declined sharply in early April, following President Donald Trump's announcement of punitive tariffs.&nbsp;Rumors that the Trump administration was eyeing stakes in quantum companies provided a solid boost to these stocks in October. D-Wave Quantum is among the best-performing publicly listed quantum companies this year,&nbsp;with gains exceeding 175%.<img src="https://news.stocktwits-cdn.com/QC_Stocks_Price_Gains_png_8e6c1e3da2.webp" alt="QC Stocks Price Gains.png">Source: KoyfinCitron Research touted in early October that Infleqtion is a&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-spac-churchill-capital-s-stock-is-jumping-premarket-today/ch6EfqhR3Ln">far better quantum play&nbsp;</a>than Rigetti.Big Tech companies have also made significant inroads in quantum computing, with Alphabet announcing its Willow quantum chip late last year. Last month, it unveiled a&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/elon-musk-tips-hat-to-sundar-pichai-for-google-s-latest-quantum-leap/cLG49mqR3Ag">breakthrough quantum algorithm,</a> dubbed “Quantum Echoes,”&nbsp;which CEO Sundar Pichai&nbsp;claims is 13,000 times faster than the best classical algorithm on one of the world's fastest supercomputers.&nbsp;That earned adulation even from Tesla CEO Elon Musk, who replied, “Looks like quantum computing is becoming relevant.”&nbsp;On Wednesday, IBM unveiled IBM Quantum Nighthawk, its most advanced quantum processor yet. As the industry makes slow and steady progress toward large-scale commercial adoption, Infleqtion finds itself in the sweet spot, positioning itself as a provider of a broad array of quantum products.<h2 class="st-heading-2">The Qubit Conundrum</h2>Kinsella said another misconception is a lack of understanding of the concept of logical qubits.&nbsp;A qubit&nbsp;is the basic unit of information in quantum computing, analogous to a bit in classical computing.He said Infleqtion holds the record for commercial qubits at 1600. “These are physical qubits, but what really matters in quantum computing are logical qubits. And logical qubits are error-corrected physical qubits.”“And it's generally thought that at 100 logical qubits, we will start to be able to do things with quantum computers that classical computers can't do.”Kinsella conceded that in terms of quantum computing, “we are not yet there.” While companies have different roadmaps for their logical qubits, Infleqtion plans to have 100 logical qubits by 2028. “So I think that's a reasonable line in the sand to say we'll start to do things that are commercially useful with quantum computers.”<h2 class="st-heading-2">Trump’s Quantum Thrust</h2>To a question about the Trump administration’s rumored interest in taking stakes in quantum computing companies, just as it invested in rare earth companies, Kinsella said such a move is possible. “I think it's the mentality of this administration to have taxpayers benefit from work that the government does with various deep tech companies.”Kinsella said the U.S. government is Infleqtion’s biggest customer and the company is constantly in talks with the government. “The topic of equity is brought up from time to time, and so I think, you know, we will continue to do a lot of business with the U.S. government, and those conversations will play out as they play out.”<h2 class="st-heading-2">China Competition</h2>It’s a race with China, just like it is in other areas. Kinsella said China is investing significantly more dollars in quantum than the U.S. has historically, but the U.S., along with its allies, invests more than China does. “But importantly, I think the U.S. is doing what it does often, and that's relying on its private capital markets to fund the innovation.”<h2 class="st-heading-2">Biggest Customer</h2>Kinsella said government accounts for more than 50% of Infleqtion’s revenue, with the Department of Defense (DoD) and government-run energy grids included in this category. The&nbsp;company also sells its clocks to non-governmental customers and academic institutions.Citing McKinsey’s research, the executive stated that Infleqtion’s total addressable market (TAM) is approximately $160 billion, comprising $30 billion in quantum sensing revenue and $130 billion in quantum computing revenue.&nbsp;<h2 class="st-heading-2">Consolidation In the Offing?</h2>While hinting that quantum computing is not a zero-sum game, Kinsella sees some degree of consolidation. “I think you'll probably end up with a handful of very large, very important quantum companies over the course of the next five to 10 years.”“One of the reasons why&nbsp;Infleqtion is going public is because I think we will be one of those consolidators, and we'll be one of those important companies. I think we have a head start now and an advantage, and we want to compound that advantage going forward.”<h2 class="st-heading-2">Government Shutdown Throws A Wrench</h2>Kinsella said Infleqtion was shooting for the end-of-the-year listing timeframe. “I hadn't really factored in the government shutdown into my calculations, and so I think it'll probably be in Q1, assuming the government gets reopened. Is it January or March? I don't know at this point.” The executive noted that the company has filed the S4 report confidentially with the SEC.<h2 class="st-heading-2">Message For Retail Investors</h2>“I personally believe quantum is going to be a very important technological shift for humanity over the course of the next decade. And I think it's great that the retail investing community is going to have more options to be able to participate in that over time,”&nbsp;Kinsella said, urging retail investors to do their due diligence. “But I think it's great that there will be the opportunity to invest in, you know, now another quantum company like Infleqtion.”“If you want to have exposure to the broad spectrum of opportunities that quantum can provide across both sensing and computing, Infleqtion is a very good way to represent that broader quantum bet.”Infleqtion will be the only publicly traded neutral-atom quantum, he said.&nbsp;That means it’s a company&nbsp;that develops quantum computers using neutral atoms, which&nbsp;lack an electrical charge. These companies use lasers to trap and manipulate these neutral atoms, arranging them into precise configurations to act as qubits for complex calculations.Kinsella thinks “neutral atoms are going to be the ones that win in quantum computing and therefore, we would be the way to express that.”For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:<a href="https://stocktwits.com/news-articles/markets/equity/intel-hit-by-ai-brain-drain-as-top-execs-depart-for-rivals/cLPdQ7DRE2w">&nbsp;Intel Hit By AI Brain Drain As Top Execs Depart For Rivals: Sachin Katti Joins OpenAI After Saurabh Kulkarni's Jump To AMD</a>

 Citron Research touted in early October that Infleqtion is a far better quantum play than Rigetti.

EXCLUSIVE: Quantum Stocks Are Still Hot — And Infleqtion's CEO Sees Industry Consolidation, $160B Opportunity As It Heads For SPAC Listing

Quantum computing company Infleqtion is set to go public via a Special Purpose Acquisition Company (SPAC) deal with Churchill Capital Corp. 

Quantum Stocks Are Still Hot — And Infleqtion's CEO Sees Industry Consolidation, $160B Opportunity As It Heads For SPAC Listing

Matt Kinsella says quantum technology will be a major technological shift for humanity over the next decade.


<ul class="summary-bullets"><li>CEO Kevin McAleenan said, with the Ask Sage deal, BigBear is creating a secure, integrated AI platform that connects software, data, and mission services in one place.</li><li>The deal is expected to close in either the fourth quarter or the first quarter of next year.</li><li>Despite the ongoing government shutdown, the company reaffirmed its 2025 revenue guidance.</li></ul>Big Bear.ai Holdings, Inc. (BBAI) stock jumped over 12% in Monday’s extended session after the company reported a third-quarter beat and announced an M&amp;A deal, buoying retail sentiment.<a href="https://stocktwits.com/symbol/BBAI">BigBear stock</a> has been on a volatile ride this year en route to its 28% year-to-date gains.&nbsp;<h2 class="st-heading-2">BigBear’s Doubled Down AI Bet</h2>The McLean, Virginia-based artificial intelligence (AI)-powered decision intelligence solutions company said it has signed an agreement to buy Ask Sage for $250 million. Ask Sage is a generative AI (GenAI) platform designed for the secure distribution of AI models and agentic AI capabilities, primarily for defense and national security agencies and other highly regulated sectors.Big Bear noted that Sage already supports more than 100,000 users on 16,000 government teams and across hundreds of commercial companies. Ask Sage is expected to deliver annual recurring revenue (ARR) of approximately $25 million in 2025, nearly six times the amount it recorded in 2024.&nbsp;CEO Kevin McAleenan said, “By integrating Ask Sage with BigBear.ai, we are creating what the market has been asking for: a secure, integrated AI platform that connects software, data, and mission services in one place.” The deal is expected to close in either the fourth quarter of 2025 or the first quarter of 2026.<h2 class="st-heading-2">BigBear’s Q3 Earnings Snapshot</h2>The net loss per share for the fiscal year 2025 fourth quarter narrowed to $0.03 from $0.06 a year ago, and revenue fell 20% year over year (YoY) to $33.1 million. The results, however, exceeded the Fiscal.ai-compiled consensus estimates for a loss of $0.07 and revenue of $31.82 million.The company blamed the YoY revenue drop on lower volume in certain Army programs, and said the narrower net loss is due to non-cash changes in the fair value of the convertible 2029 notes and warrants.&nbsp;Gross margin contracted 350 basis points YoY due to the absence of some high-margin programs that benefited the year-ago quarter.BigBear ended the quarter with a backlog of $376 million.<h2 class="st-heading-2">BigBear’s Outlook</h2>Despite the ongoing government shutdown, the company reaffirmed its 2025 revenue guidance of $125 million to $140 million, which aligns with the consensus estimate of $133.53 million.<h2 class="st-heading-2">What BigBear Retail Feels About Stock After Q3 Print</h2>On Stocktwits, retail sentiment toward the stock shifted to ‘bullish’ as of early Tuesday, from ‘bearish’ a day ago. The 24-hour message volume leading up to late&nbsp; Monday surged up by about 1,500%.<figure class="image"><img style="aspect-ratio:677/58;" src="https://news.stocktwits-cdn.com/Screenshot_2025_11_11_at_12_27_52_AM_png_f6bac86ee7.webp" alt="Screenshot 2025-11-11 at 12.27.52 AM.png" width="677" height="58"><figcaption>BBAI sentiment and message volume as of 2:25 a.m. ET, Nov. 11 | source: Stocktwits</figcaption></figure>A bullish watcher said there is a good chance the stock will open above $7 on Tuesday.<stembedurl>https://stocktwits.com/MyEfund/message/635695260</stembedurl>Another user expressed comfort in&nbsp;holding the stock. “I don’t feel as bad holding this stock anymore after today’s earnings call.”<stembedurl>https://stocktwits.com/DARK_SCROOGIE/message/635690861</stembedurl>The average analysts' price target for BigBear stock is $5.83, according to Koyfin, implying roughly 2% upside from Monday's closing price.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/intel-hit-by-ai-brain-drain-as-top-execs-depart-for-rivals/cLPdQ7DRE2w">Intel Hit By AI Brain Drain As Top Execs Depart For Rivals: Sachin Katti Joins OpenAI After Saurabh Kulkarni's Jump To AMD</a>

The logo of BigBear.ai Holdings, Inc. displayed on a smartphone screen, with the company's latest stock market chart visible in the background on April 26, 2025, in Chongqing, China. (Photo illustration credit: Cheng Xin/Getty Images)

BigBear Stock Surges Over 12% After-Hours On $250M Ask Sage Deal, Q3 Beat — Retail Impressed With Results

BigBear announced a strategic acquisition of a GenAI platform, which is growing revenue at a scorching pace.

BigBear Stock Surges Over 12% After-Hours On $250M Ask Sage Deal, Q3 Beat

<ul class="summary-bullets"><li>According to Fiscal.ai-compiled consensus, BigBear is expected to report a loss per share of $0.07 and revenue of $31.82 million.</li><li>During the quarter, the company announced several deals, including one that aims to deploy advanced AI and orchestration technologies in support of the U.S. Navy.</li><li>BigBear stock is up about 17.7% YTD.</li></ul>Big Bear.ai Holdings, Inc. (BBAI) stock rallied nearly 4% in premarket trade ahead of the company’s quarterly earnings report, due after the market closes on Monday. The artificial intelligence (AI)-powered decision intelligence solutions firm has attracted attention from retail traders, even as analysts forecast a wider loss and lower revenue compared to last year.For the year-to-date period,&nbsp;<a href="https://stocktwits.com/symbol/BBAI">BigBear stock</a> has gained about 17.7%, underperforming the broader market and the tech sector.<h2 class="st-heading-2">Retail Excited About BigBear’s Q3</h2>When retail users of the Stocktwits platform were asked which earnings report they were most excited for the week of Nov.10, a majority picked BigBear, reflecting interest in the stock. An ongoing poll that has received responses from 11,200 users so far has shown that 30% are excited about BigBear’s earnings. AST SpaceMobile (ASTS), Nebius N.V. (NBIS) and Rocket Lab (RKLB) were mentioned by 25%, 23% and 22% of the respondents, respectively.<a href="https://stocktwits.com/StocktwitsPolls/message/635353734"><img src="https://news.stocktwits-cdn.com/Screenshot_2025_11_10_at_4_37_04_AM_png_a62853f334.webp" alt="Screenshot 2025-11-10 at 4.37.04 AM.png"></a>A Stocktwits user hoped the stock would gain enough momentum to hit double digits before Christmas, based on the view that BigBear's earnings report would not be too bad. Another user stated that the stock is poised to take off and will continue rallying until the end of the year. They set their sights on $12.<stembedurl>https://stocktwits.com/Paul243/message/635557229</stembedurl><stembedurl>https://stocktwits.com/Ohad12/message/635559688</stembedurl>A third user said he would continue to stack the stock.<stembedurl>https://stocktwits.com/marzo34/message/635554283</stembedurl><h2 class="st-heading-2">What Analysts Expect From BigBear’s Q3 Print</h2>According to Fiscal.ai-compiled consensus, BigBear is expected to report a loss per share of $0.07 and revenue of $31.82 million. This compares to the year-ago’s loss per share of $0.05 and revenue of $41.51 million.During the quarter, the company announced several deals, including one that aims to deploy advanced AI and orchestration technologies in support of the U.S. Naval Forces Southern Command. The company also announced a strategic partnership with Tsecond to deliver AI-enabled edge infrastructure for mission-critical operations.The average analysts’ price target for BigBear stock is $5.83, according to Koyfin, implying roughly 2.70% potential upside.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-rumble-stock-is-soaring-nearly-16-in-premarket/cLPcX3hREcH">Why Rumble Stock Is Soaring Nearly 16% In Premarket</a>

In this photo illustration, a person holds a smartphone displaying the logo of BigBear.ai Holdings, Inc. (NYSE: BBAI), on August 8, 2025, in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images)

BigBear Retail’s Top Earnings Pick Of The Week Ahead: Stock Gains Nearly 4% Premarket Ahead Of Q3 

BigBear retail is buzzing about the stock taking off and rallying through the year-end.

<ul class="summary-bullets"><li>Strive, following its merger with Asset Entities in mid-September, announced plans to become a Bitcoin holding company.</li><li>Bitcoin topped the $116K earlier in the Asian session, before giving back some of the gains.</li><li>The optimism toward cryptocurrencies stemmed from a raft of catalysts, including the brightening prospects of a U.S.-China deal.</li></ul>Strive Asset Management, LLC (ASST) stock climbed sharply in Monday’s early premarket session, signaling that it may rise for a third consecutive session.On Stocktwits, retail sentiment toward&nbsp;<a href="https://stocktwits.com/symbol/ASST">Strive stock</a> remained ‘extremely bullish’ as of early Monday, and the message volume jumped to ‘extremely high’ levels.<h2 class="st-heading-2">Strive’s Bitcoin-Inspired Rally?</h2>Nasdaq-listed Asset Entities, a marketing company, closed its merger with asset management company Strive in mid-September, retaining the Strive name and ‘ASST’ ticker. The company, co-founded by Vivek Ramaswami, announced plans to become a Bitcoin (BTC) holding and marketing company.ASST’s premarket gains on Monday could be traced to strong gains in Bitcoin (BTC), which topped the $116K earlier in the Asian session,&nbsp;before giving back some of the gains. The optimism toward crypto stemmed from a raft of catalysts, including the brightening prospects of a U.S.-China deal following productive high-level talks between the two countries in Malaysia over the weekend.Hopes of a rate cut from the Federal Reserve’s rate-setting committee, when it meets for a two-day meeting that kicks off on Tuesday, also lent support to cryptocurrencies.<h2 class="st-heading-2">What Retail’s Feeling About Strive Stock</h2>Retail’s interest in Strive’s stock has been on the rise, with the one-year follower count rising 675% and the message volume over the past seven days leading up to late Sunday was up over 900%.A bullish watcher lauded the company for the bold move to merge and become the first public Bitcoin treasury company, backed by a massive $750 million funding plan. “Big vision, big potential!” they said.<stembedurl>https://stocktwits.com/StockGuru95/message/633790891</stembedurl>Another user expected algorithmic buying on Monday, just like last Friday, when it ripped before remaining stuck for a long time.<stembedurl>https://stocktwits.com/Ammylovlov/message/633790840</stembedurl>Since its mid-September listing, the stock has lost about 82%. In premarket, the stock climbed over 26% on top of Friday’s 27%+ rally.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-avidity-biosciences-stock-is-jumping-over-43-in-premarket-today/cLG0dICR3Ma">Why Avidity Biosciences Stock Is Jumping Over 43% In Premarket Today</a>

Why Strive Stock Is Ripping Higher In Premarket Today

Strive Asset Management, LLC (ASST) stock climbed sharply in Monday’s early premarket session, signaling that it may rise for a third consecutive session.

Why Strive (ASST) Stock Is Ripping Higher In Premarket Today

<ul class="summary-bullets"><li>Novartis has agreed to buy Avidity Biosciences in a deal valued at $72 per share.</li><li>The deal is expected to close in the first half of 2026.</li><li>Retail sentiment toward Avidity Biosciences stock flipped to ‘extremely bullish’ by early Monday from ‘bearish’ a day ago.</li></ul>Avidity Biosciences, Inc. (RNA) shares&nbsp;soared over 43% in Monday’s early premarket session after the mid-cap biopharma focusing on developing RNA therapeutics called antibody oligonucleotide conjugates (AOC), announced a deal to be bought by Swiss pharma giant Novartis (NVS).<a href="https://stocktwits.com/symbol/RNA">Avidity Biosciences</a> stock has gained more than 60% this year.<h2 class="st-heading-2">The Novartis Deal Terms</h2>In a statement released on Sunday, Novartis said it would acquire San Diego-based Avidity Biosciences following the separation of the latter’s early-stage precision cardiology programs. The deal, approved by the boards of both companies, is valued at $72 per share in cash. This represented a 46% premium over RNA stock’s closing price of $49.15 on Friday.The total transaction value is $12 billion on a fully diluted basis. Avidity Biosciences currently boasts a market capitalization of $7.17 billion.Vas Narasimhan, CEO of Novartis, said, “Avidity’s pioneering AOC platform for RNA therapeutics ​and its late-stage assets bolster our commitment to delivering innovative, targeted, and potentially first-in-class medicines to treat devastating, progressive neuromuscular diseases.”Before the merger's closing, Avidity will transfer its early-stage precision cardiology programs and collaborations to SpinCo, a wholly owned subsidiary of Avidity. Holders of Avidity common stock will receive a distribution of one share of SpinCo for every ten shares of Avidity they hold and/or a pro rata cash distribution of the proceeds received by Avidity before the closing if certain SpinCo assets are, or SpinCo itself is, sold to a third party.The deal is expected to close in the first half of 2026, subject to the completion of a spin-off or the sale of SpinCo and other customary closing conditions, including the receipt of regulatory approvals and the approval of Avidity stockholders.Novartis said the proposed acquisition raises the expected 2024-2029 sales growth from 5% to 6% on a compounded annual growth rate (CAGR) basis, representing a significant opportunity to deliver substantial shareholder returns over time.<h2 class="st-heading-2">What Retail’s Saying About The Buyout Deal</h2>Retail sentiment toward Avidity Biosciences stock flipped to ‘extremely bullish’ by early Monday from ‘bearish’ a day ago. The message volume on the stream also improved to ‘extremely high.’&nbsp; Retail chatter spiked 6,100% over the 24 hours leading up to late Sunday.<figure class="image"><img style="aspect-ratio:620/56;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_27_at_6_02_00_AM_png_9d47ea362a.webp" alt="Screenshot 2025-10-27 at 6.02.00 AM.png" width="620" height="56"><figcaption>RNA sentiment and message volume as of 6 a.m. ET, Oct. 27 | source: Stocktwits</figcaption></figure>A bullish user noted that RNA traded at $5 two years ago and congratulated the believers.<stembedurl>https://stocktwits.com/Cutlass/message/633766787</stembedurl>Another user said they would cash out on Monday.<stembedurl>https://stocktwits.com/ure300/message/633760283</stembedurl>Earlier this month, Avidity Biosciences said it has completed a positive pre-Biologic License Application (BLA) meeting with the FDA regarding its delpacibart zotadirsen, an investigational drug being evaluated as a potential treatment for people living with Duchenne muscular dystrophy (DMD) who have gene mutations amenable to exon 44 skipping.&nbsp;The timing for the BLA submission was pushed back to the first quarter of 2026 from the previous guidance of year-end 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/palantir-rises-premarket-today-as-stock-closes-in-on-200-psychological-threshold/cLG0TBNR3Md">Palantir Rises Premarket Today As Stock Closes In On $200 Psychological Threshold: What’s Driving The Gains?</a>

Researcher performing microbiology separator for PCR diagnosis test in pathology laboratory. 

Why Avidity Biosciences Stock Is Jumping Over 43% In Premarket Today

Novartis has agreed to buy Avidity Biosciences in a deal valued at $72 per share.

Why Avidity Biosciences Stock Is Jumping Over 40% In Premarket Today

&nbsp;<ul class="summary-bullets"><li>In an amended&nbsp;regulatory filing, AiRWA confirmed a stake built by director Michael Anthony Belfiore.</li><li>According to the filing, he now holds a 22.1% stake in AiRWA.</li><li>Retail expects “FOMO” fear will kick in once the stock reaches $0.50.</li></ul>Nano-cap AiRWA, Inc.’s (YYAI) stock fell for two consecutive sessions this week, but rebounded by nearly 32% in Tuesday’s after-hours session, accompanied by substantial volume,&nbsp;following a filing by the company confirming an insider’s stake build.<a href="https://stocktwits.com/symbol/YYAI">AiRWA stock</a>, which has traded in a 52-week range of $0.0670 to $6.33, has elicited a strong bullish reaction from retail traders.<h2 class="st-heading-2">Insider Accumulates AiRWA Stock</h2>In an amended Schedule 13D filing with the SEC, AiRWA confirmed the stake build by director Michael Anthony Belfiore, which the company disclosed earlier this month. A Schedule 13D is filed by a person who acquires more than 5% of a voting class of a company’s stock, and who does not otherwise qualify to file a short-form report on Schedule 13G. It has to be filed within 10 days of the purchase of more than 5% stake.&nbsp;The company filed a Form 4 with the SEC on Oct. 15, stating that Belfiore purchased 3.21 million AiWA stock shares between Oct. 8 and Oct. 10, valued at $1.03 million. According to the 13D filing, Belfiore now holds a 22.1% stake in AiRWA.AiRWA, formerly Connexa Sports Technologies, rebranded itself to the present name on Oct. 7, underlining its thrust into the Web3 space and blockchain technology. In late August, the company, which was then called Connex Sports, struck a $500 million agreement with Singapore-based JuCoin to establish aiRWA, a next-generation digital asset platform jointly.&nbsp;According to the companies, the venture will focus on real-world asset (RWA) tokenization aimed at bringing traditional investments such as real estate, government bonds, and fine arts into a digital format. As part of the deal, JuCoin committed a $100 million investment in AiRWA, including about $30 million of Solana (SOL) tokens.<h2 class="st-heading-2">How Retail Feels About AiRWA Stock</h2>On Stocktwits, retail sentiment toward AiRWA stock shifted to ‘extremely bullish’ from the ‘bullish’ mood seen a day ago. The message volume remained at ‘extremely high’ levels. Retail chatter spiked nearly 3,500% in the 24 hours leading up to late Tuesday.<figure class="image"><img style="aspect-ratio:621/57;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_22_at_1_55_49_AM_png_5452a973dc.webp" alt="Screenshot 2025-10-22 at 1.55.49 AM.png" width="621" height="57"><figcaption>YYAI sentiment and message volume as of 1:55 a.m. ET, Oct. 22 | source: Stocktwits</figcaption></figure>One bullish user said “FOMO” fear will kick in once the stock reaches $0.50, and predicted a move to $1. Another user noted that retail traders’ support could push the price past the level.<stembedurl>https://stocktwits.com/ineedmore/message/633174405</stembedurl><stembedurl>https://stocktwits.com/ineedmore/message/633172951</stembedurl>AirWA stock, which fell 19.18% on Tuesday to $0.0809, was seen jumping 44% in overnight trading, according to Yahoo Finance.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-pega-stock-surge-over-13-in-after-hours-trading/cLGPxWaR3pl">Why Did PEGA Stock Surge Over 13% In After-Hours Trading?</a>

YYAI Stock Rockets After Insider Buying Reveal: Retail Trader FOMO Builds

In an amended regulatory filing, AiRWA confirmed a stake built by director Michael Anthony Belfiore.

Current Price	$163.90
Prev Close	$166.46
Open	$165.66
Dividend Yield	N/A
50-Day Moving Average	$154.37
Beta	N/A
Avg. Volume	54,855.47
PE Ratio	N/A

52-Week High	$166.93
52-Week Low	$95.25
Market Capitalization	N/A
EPS (Annual)	N/A
Price to Book	N/A
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

IWC
iShares Micro-Cap ETF

Feed

News

Sentiment

Fundamentals

Info

Latest IWC News

IWCiShares Micro-Cap ETF